Post hoc analyses of these studies have since shown that microsatellite instable (MSI-H), high PD-L1 expressors with CPS ≥ 10 and tumour mutational burden (TMB, defined as ≥10 mutations/Mb) can identify patients most likely to benefit from pembrolizumab and indicate that these parameters could facilitate patient selection for ICIs [16]. The gene discussed is CD274; the disease is neoplasm.